AAIC 2025 Abstract
MINDFuL: a Multi‐center, Randomized, Double‐blind, Placebo‐controlled Phase 2 Clinical Trial of XPro1595 for Patients with Early Alzheimer's Disease and Biomarkers of Inflammation
Trial in peopleInterventions
Abstract
Background: Dysfunctional inflammatory/immune processes are recognized as key contributors to the pathogenesis and progression of Alzheimer's Disease (AD).
